

Exploristics | Transforming Clinical Trial Design Overview
Summary
Exploristics | Transforming Clinical Trial Design is a private company that has been in the industry for 16 years. The company currently specializes in the Biotechnology, Business Support Services, Business Information Research areas. The position of the CEO is occupied by Aiden Flynn. Its headquarters is located at Belfast, Northern Ireland, GB. The number of employees ranges from 25 to 100. The annual revenue of Exploristics | Transforming Clinical Trial Design varies between 100K and 5.0M. Total funding of the company - $1.3M. To connect with Exploristics | Transforming Clinical Trial Design employee register on SignalHire.
Exploristics | Transforming Clinical Trial Design industries
Biotechnology
Headquarters Location
Exploristics | Transforming Clinical Trial Design Employees Size
100-200 employees
Specialties
Modeling, Biomarkers, Pharmacogenomics, Biosimulation software, Biostatistics Services, Data Science Services, Statistical Consulting Services, Clinical trial design, Synthetic Data generation, Clinical trial reporting, Precision medicine, Data analytics, Statistical analysis planning and execution, Clinical protocol development, Sample size /power calculations, Regulatory submission and meeting support, Innovative study design and analysis methods, Optimising protocol and analysis plan amendments, Bayesian analysis for study design and reporting, Implementing the estimands framework, Statistical programming, Integration of real-world data, External control arm reviews, Clinical endpoint review and analysis
SIC Code
7380, 8700
Founded
2009
Estimated Annual Revenue
$100K - 5.0M
Operating Status
Independent Company
Contact Exploristics | Transforming Clinical Trial Design
Organization Website
Social Links
Phone Number
028-9600-1996
Exploristics | Transforming Clinical Trial Design Competitors
Founded | Type | Employees | Revenue | Funding | |
---|---|---|---|---|---|
1993 | Privately Held | 500 - 1.0K | 45M | $5M | |
1980 | Public Company | 1.0K - 5.0K | 281.9M | $49.5M | |
1999 | Privately Held | 1.0K - 5.0K | 165M | $5M | |
2003 | Privately Held | 500 - 1.0K | 122M | $158.7M | |
2012 | Privately Held | 100 - 250 | 23.1M | $19.3M | |
2000 | Privately Held | 1.0K - 5.0K | 125M | $3.4M | |
2007 | Privately Held | 100 - 250 | 22.5M | $27.4M | |
2014 | Privately Held | 100 - 250 | 7.8M | $89.2M | |
1999 | Public Company | 1.0K - 5.0K | 635.7M | $88.2M | |
1999 | Privately Held | 25 - 100 | 10M | $0 | |
1972 | Public Company | 100K - 9.9M | 34.1B | $0 | |
1967 | Privately Held | 1.0K - 5.0K | 467.6M | $0 | |
1959 | Public Company | 50K - 100K | 5.5B | $0 | |
2009 | Privately Held | 100 - 250 | 11.6M | $0 | |
2005 | Privately Held | 1 - 25 | 10M | $0 | |
1977 | Privately Held | 1.0K - 5.0K | 559.9M | $0 | |
1982 | Privately Held | 10K - 50K | 2.5B | $0 | |
1983 | Privately Held | 25 - 100 | 66.8M | $0 | |
1990 | - | 1000-5000 | - | $- | |
2008 | - | 100-200 | - | $- | |
1987 | - | 1000-5000 | - | $- | |
- | - | 5000-10000 | - | $- | |
- | - | 200-500 | - | $- | |
- | - | 10000+ | - | $- |